GlassScriptPhysician profile
Alayna Link
NPI 1740773373
$3,273.07
in general payments reported to CMS, 2019-2025
29 companies · $596 in 2025
The $596 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $587 · 2023: $1,017 · 2024: $825 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $671.85 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $359.78 | 2021-2025 | Andexxa, Farxiga, Lokelma |
| Pfizer INC. | $274.23 | 2022-2025 | |
| Novo Nordisk INC | $236.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.00 | 2021-2025 | Jardiance |
| Cvrx, INC. | $183.21 | 2022-2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $149.89 | 2024-2025 | Onpattro |
| Heartflow, INC. | $122.53 | 2022-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $101.75 | 2021-2024 | Xarelto |
| Daiichi Sankyo INC. | $100.87 | 2023-2025 | Injectafer |
| Amgen INC. | $99.77 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $85.54 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $82.26 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $69.29 | 2022-2024 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $67.08 | 2023-2025 | Camzyos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $64.12 | 2024 | Arcalyst |
| Abbott Laboratories | $62.11 | 2023-2024 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $46.74 | 2023-2025 | |
| United Therapeutics Corporation | $45.96 | 2023-2024 | Tyvaso |
| Scpharmaceuticals INC. | $39.28 | 2025 | |
| Amarin Pharma, INC. | $34.74 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $33.83 | 2023 | Arcalyst |
| Boston Scientific Corporation | $27.17 | 2025 | Watchman |
| Abiomed | $23.55 | 2023 | Impella |
| Edwards Lifesciences Corporation | $19.66 | 2023 | |
| Astellas Pharma US INC | $18.26 | 2022 | |
| Tactile Systems Technology INC | $14.85 | 2024 | Flexitouch Plus, Entre Plus |
| Sanofi-Aventis U.S. LLC | $13.65 | 2023 | |
| Merck Sharp & Dohme LLC | $13.54 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alayna Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.